Literature DB >> 15606386

Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease?

T J Lee1, M B Fennerty, C W Howden.   

Abstract

BACKGROUND: Proton-pump inhibitors are often recommended for continuous use in gastro-oesophageal reflux disease, but this may not be necessary in all patients. AIM: To ascertain the level of evidence for alternative strategies for proton-pump inhibitor treatment in gastro-oesophageal reflux disease.
METHODS: We searched for observational or interventional studies examining alternatives to continuous proton-pump inhibitor treatment in gastro-oesophageal reflux disease.
RESULTS: Non-randomized studies suggest that some patients with gastro-oesophageal reflux disease, including some with erosive oesophagitis, may be adequately maintained on proton-pump inhibitor therapy given less frequently than once daily. However, the results may not be generalizable. Four high quality randomized-controlled trials compared 'on-demand' proton-pump inhibitor and placebo treatment in endoscopy-negative reflux disease; all found this effective for most patients. One high quality randomized-controlled trial found intermittent courses of a proton-pump inhibitor or H2-receptor antagonist in erosive oesophagitis or endoscopy-negative reflux disease adequate for almost half of the patients studied. Up to 80% of patients on continuous high-dose proton-pump inhibitor treatment for gastro-oesophageal reflux disease can be 'stepped down' to less intensive therapy.
CONCLUSIONS: On-demand proton-pump inhibitor treatment may be appropriate in endoscopy-negative reflux disease. In gastro-oesophageal reflux disease, patients taking more than once daily or high-dose proton-pump inhibitor treatment, a step down to once daily or standard dose therapy should be attempted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15606386     DOI: 10.1111/j.1365-2036.2004.02289.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

Review 1.  Medicare Part D's effect on the under- and overuse of medications: a systematic review.

Authors:  Jennifer M Polinski; Julie M Donohue; Elaine Kilabuk; William H Shrank
Journal:  J Am Geriatr Soc       Date:  2011-08-01       Impact factor: 5.562

Review 2.  Endoluminal therapy for gastroesophageal reflux disease: is the evidence for efficacy any stronger?

Authors:  Thomas J Lee; Peter J Kahrilas
Journal:  Curr Gastroenterol Rep       Date:  2005-06

3.  Intravenous pantoprazole utilization in a level 1 trauma center.

Authors:  David A Edelman; Krupa R Patel; James G Tyburski; Lisa G Hall Zimmerman
Journal:  Surg Endosc       Date:  2007-08-21       Impact factor: 4.584

4.  The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits.

Authors:  Sebastian Schneeweiss; Amanda R Patrick; Alex Pedan; Laleh Varasteh; Raisa Levin; Nan Liu; William H Shrank
Journal:  Health Aff (Millwood)       Date:  2009-02-03       Impact factor: 6.301

5.  Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.

Authors:  D G Morgan; M F J O'Mahony; W F O'Mahony; J Roy; F Camacho; J Dinniwell; G L A Horbay; F A Husein-Bhabha
Journal:  Can J Gastroenterol       Date:  2007-12       Impact factor: 3.522

Review 6.  Deprescribing versus continuation of chronic proton pump inhibitor use in adults.

Authors:  Taline A Boghossian; Farah Joy Rashid; Wade Thompson; Vivian Welch; Paul Moayyedi; Carlos Rojas-Fernandez; Kevin Pottie; Barbara Farrell
Journal:  Cochrane Database Syst Rev       Date:  2017-03-16

7.  Clinical medication reviews in elderly patients with polypharmacy: a cross-sectional study on drug-related problems in the Netherlands.

Authors:  Sek Hung Chau; Aaltje P D Jansen; Peter M van de Ven; Petra Hoogland; Petra J M Elders; Jacqueline G Hugtenburg
Journal:  Int J Clin Pharm       Date:  2015-11-23

Review 8.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.